Acurx Pharmaceuticals Inc (ACXP)

$0.47 -0.01 (-2.20%)
Market Cap 11.32M
Revenue (ttm) 0.00
Net Income (ttm) -14.10M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 691,474
Avg Vol 7,580,824
Day's Range N/A - N/A
Shares Out 23.48M
Stochastic %K 26%
Beta -1.23
Analysts Strong Sell
Price Target $4.83

Company Profile

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant st...

Industry: Biotechnology
Sector: Healthcare
Phone: 917 533 1469
Address:
259 Liberty Avenue, Staten Island, United States
lentl1cker
lentl1cker Jul. 7 at 7:39 PM
$ACXP Good things come to those who wait all my Bulls be patient she will pop and all of it will be well worth it I fully expect a minimum of 4$ a share
1 · Reply
Nanananananana
Nanananananana Jul. 7 at 6:05 PM
$ACXP is this ever gonna come out with news?
0 · Reply
Nanananananana
Nanananananana Jul. 7 at 4:19 PM
$ACXP idiot 👇🏼
0 · Reply
sssssssssssssAhmed
sssssssssssssAhmed Jul. 7 at 3:15 PM
$ACXP hhhhhhhh. Expected to delist
1 · Reply
Nanananananana
Nanananananana Jul. 7 at 2:35 PM
$ACXP this stock and company are ☠️
0 · Reply
Nanananananana
Nanananananana Jul. 7 at 2:35 PM
$ACXP pos
0 · Reply
Bonso99
Bonso99 Jul. 7 at 2:07 PM
$ACXP 👀👀👀👀👀
0 · Reply
Nanananananana
Nanananananana Jul. 7 at 10:23 AM
$ACXP 🚀🚀🚀
0 · Reply
Nanananananana
Nanananananana Jul. 5 at 11:43 PM
$ACXP hot trash
2 · Reply
Bulltrader988
Bulltrader988 Jul. 4 at 7:21 PM
$ACXP 👃👀
0 · Reply
Latest News on ACXP
Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds

Jun 17, 2025, 9:47 PM EDT - 19 days ago

Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds

Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI

Jun 17, 2025, 7:01 AM EDT - 20 days ago

Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference

Jun 9, 2025, 7:30 AM EDT - 4 weeks ago

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2025 Earnings Call Transcript

May 13, 2025, 1:59 PM EDT - 7 weeks ago

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2025 Earnings Call Transcript

Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update

May 13, 2025, 7:01 AM EDT - 7 weeks ago

Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update

Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update

Apr 30, 2025, 7:30 AM EDT - 2 months ago

Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

Apr 28, 2025, 7:30 AM EDT - 2 months ago

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

Apr 17, 2025, 7:30 AM EDT - 2 months ago

Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 9:44 AM EDT - 3 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2024 Earnings Call Transcript

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 18, 2025, 7:01 AM EDT - 3 months ago

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering

Mar 10, 2025, 4:30 PM EDT - 4 months ago

Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering

Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering

Mar 7, 2025, 8:00 AM EST - 4 months ago

Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering

Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics

Mar 3, 2025, 8:00 AM EST - 4 months ago

Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update

Feb 28, 2025, 8:00 AM EST - 4 months ago

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

Feb 24, 2025, 8:00 AM EST - 4 months ago

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors

Feb 19, 2025, 8:00 AM EST - 4 months ago

JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors

Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 7, 2025, 5:00 PM EST - 6 months ago

Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 6, 2025, 5:35 PM EST - 6 months ago

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)

Jan 6, 2025, 8:30 AM EST - 6 months ago

Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)

Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025

Dec 11, 2024, 11:00 AM EST - 7 months ago

Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications

Dec 9, 2024, 8:00 AM EST - 7 months ago

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications

Acurx Pharmaceuticals to add up to $1 million in bitcoin for treasury reserve, following MicroStrategy's playbook

Nov 20, 2024, 10:53 AM EST - 8 months ago

Acurx Pharmaceuticals to add up to $1 million in bitcoin for treasury reserve, following MicroStrategy's playbook

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset

Nov 20, 2024, 7:01 AM EST - 8 months ago

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset

Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update

Nov 18, 2024, 7:00 AM EST - 8 months ago

Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update

Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 11:43 AM EST - 8 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update

Nov 13, 2024, 7:00 AM EST - 8 months ago

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update

Acurx Ready To Expand Pipeline With Anthrax Treatment

Oct 21, 2024, 10:07 AM EDT - 9 months ago

Acurx Ready To Expand Pipeline With Anthrax Treatment

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference

Oct 21, 2024, 7:00 AM EDT - 9 months ago

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference

Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement

Oct 17, 2024, 8:00 AM EDT - 9 months ago

Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement

Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024

Oct 16, 2024, 8:00 AM EDT - 9 months ago

Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024

New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support

Oct 14, 2024, 1:00 PM EDT - 9 months ago

New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support

New to the Street Announces Exclusive Bloomberg Lineup for October 11 at 6:30 PM EST

Oct 11, 2024, 10:50 AM EDT - 9 months ago

New to the Street Announces Exclusive Bloomberg Lineup for October 11 at 6:30 PM EST

Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues

Sep 26, 2024, 7:00 AM EDT - 10 months ago

Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues

Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium

Sep 24, 2024, 7:00 AM EDT - 10 months ago

Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium

ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 7:00 AM EDT - 11 months ago

ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference

Acurx Pharmaceuticals, Inc. (ACXP) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 10:20 AM EDT - 11 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q2 2024 Earnings Call Transcript

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update

Aug 9, 2024, 7:01 AM EDT - 11 months ago

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update

USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome

Jul 17, 2024, 7:00 AM EDT - 1 year ago

USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome

Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update

Jul 16, 2024, 7:00 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference

Jul 15, 2024, 7:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2024 Earnings Call Transcript

May 15, 2024, 1:14 PM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2024 Earnings Call Transcript

Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection

May 15, 2024, 9:00 AM EDT - 1 year ago

Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection

Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update

May 15, 2024, 7:00 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference

May 2, 2024, 7:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference

Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference

Apr 25, 2024, 10:12 AM EDT - 1 year ago

Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference

Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update

Apr 23, 2024, 10:57 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update

Acurx Pharmaceuticals, Inc. Announces Participation in the LD Micro Invitational XIV

Mar 21, 2024, 7:01 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Announces Participation in the LD Micro Invitational XIV

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call Transcript

Mar 18, 2024, 11:19 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call Transcript

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Mar 18, 2024, 7:01 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update

Mar 4, 2024, 7:01 AM EST - 1 year ago

Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update

lentl1cker
lentl1cker Jul. 7 at 7:39 PM
$ACXP Good things come to those who wait all my Bulls be patient she will pop and all of it will be well worth it I fully expect a minimum of 4$ a share
1 · Reply
Nanananananana
Nanananananana Jul. 7 at 6:05 PM
$ACXP is this ever gonna come out with news?
0 · Reply
Nanananananana
Nanananananana Jul. 7 at 4:19 PM
$ACXP idiot 👇🏼
0 · Reply
sssssssssssssAhmed
sssssssssssssAhmed Jul. 7 at 3:15 PM
$ACXP hhhhhhhh. Expected to delist
1 · Reply
Nanananananana
Nanananananana Jul. 7 at 2:35 PM
$ACXP this stock and company are ☠️
0 · Reply
Nanananananana
Nanananananana Jul. 7 at 2:35 PM
$ACXP pos
0 · Reply
Bonso99
Bonso99 Jul. 7 at 2:07 PM
$ACXP 👀👀👀👀👀
0 · Reply
Nanananananana
Nanananananana Jul. 7 at 10:23 AM
$ACXP 🚀🚀🚀
0 · Reply
Nanananananana
Nanananananana Jul. 5 at 11:43 PM
$ACXP hot trash
2 · Reply
Bulltrader988
Bulltrader988 Jul. 4 at 7:21 PM
$ACXP 👃👀
0 · Reply
Nanananananana
Nanananananana Jul. 3 at 7:33 PM
$ACXP why does this company suck so much?
0 · Reply
flcountryboy
flcountryboy Jul. 3 at 4:43 PM
$ACXP Damm it! Summit is getting all the attention and a deal for CDi treatment! What does this do to ACXP treatment? How did Summit get ahead of this on ACXP?
1 · Reply
Nanananananana
Nanananananana Jul. 3 at 3:40 PM
$ACXP trash
1 · Reply
Nanananananana
Nanananananana Jul. 3 at 1:32 AM
$ACXP everyday this goes down
0 · Reply
Bavaro89
Bavaro89 Jul. 2 at 7:38 PM
$ACXP 🧨
0 · Reply
Nanananananana
Nanananananana Jul. 2 at 6:07 PM
$ACXP
0 · Reply
sssssssssssssAhmed
sssssssssssssAhmed Jul. 2 at 2:16 PM
$ACXP keep buying. Your money will be zero dollar after less than one year.
2 · Reply
lentl1cker
lentl1cker Jul. 2 at 2:12 PM
$ACXP please everyone keep selling drive it done so I can keep buying these cheap shares sitting at 11k shares now looking to keep loading more
1 · Reply
Nanananananana
Nanananananana Jul. 2 at 1:56 PM
$ACXP yea keep going down you pos
0 · Reply
Nanananananana
Nanananananana Jul. 2 at 1:46 PM
$ACXP breakout drug my ass. I lost thousands on this junk.
0 · Reply
Nanananananana
Nanananananana Jul. 2 at 1:21 PM
$ACXP I’m out today too. Tired of this scam
0 · Reply
Kari66
Kari66 Jul. 2 at 1:01 PM
$ACXP yea im selling by eod today if this doesnt sart moving
0 · Reply